AngioDynamics, Inc. (NASDAQ:ANGO) Receives Average Recommendation of “Hold” from Brokerages
AngioDynamics, Inc. (NASDAQ:ANGO) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $18.40.
ANGO has been the subject of a number of recent analyst reports. Barclays PLC dropped their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. BidaskClub lowered AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered AngioDynamics from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th. Cantor Fitzgerald upped their price objective on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $17.00 price objective on shares of AngioDynamics in a research note on Tuesday, July 18th.
In other news, CEO James C. Clemmer bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The shares were bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James C. Clemmer bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was purchased at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Insiders purchased 25,316 shares of company stock worth $396,806 over the last quarter. 1.88% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the company. Norges Bank purchased a new stake in AngioDynamics during the fourth quarter worth approximately $2,699,000. Teachers Advisors LLC increased its stake in AngioDynamics by 33.2% in the fourth quarter. Teachers Advisors LLC now owns 83,187 shares of the medical instruments supplier’s stock worth $1,403,000 after buying an additional 20,754 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in AngioDynamics by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 13,000 shares of the medical instruments supplier’s stock worth $226,000 after buying an additional 300 shares in the last quarter. Perkins Capital Management Inc. increased its stake in AngioDynamics by 5.8% in the first quarter. Perkins Capital Management Inc. now owns 54,850 shares of the medical instruments supplier’s stock worth $952,000 after buying an additional 3,000 shares in the last quarter. Finally, Sawgrass Asset Management LLC purchased a new stake in AngioDynamics during the first quarter worth approximately $282,000. Institutional investors own 85.84% of the company’s stock.
AngioDynamics (NASDAQ:ANGO) traded up 0.55% during mid-day trading on Friday, hitting $16.36. The company’s stock had a trading volume of 157,969 shares. The stock has a market cap of $598.45 million, a P/E ratio of 119.42 and a beta of 1.15. AngioDynamics has a 52-week low of $14.80 and a 52-week high of $18.18. The company’s 50 day moving average is $16.21 and its 200-day moving average is $16.17.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.03. The firm had revenue of $86.90 million during the quarter, compared to analyst estimates of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.19 earnings per share. On average, equities analysts predict that AngioDynamics will post $0.67 EPS for the current fiscal year.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.